Health Care & Life Sciences » Pharmaceuticals | Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
102,712.00
121,042.00
205,912.00
142,086.00
136,411.00
107,776
Total Accounts Receivable
1,706.00
3,458.00
4,151.00
1,789.00
4,653.00
5,274
Other Current Assets
1,002.00
2,097.00
3,705.00
6,582.00
6,382.00
2,674
Total Current Assets
105,420.00
126,597.00
213,768.00
150,457.00
147,446.00
116,472
Net Property, Plant & Equipment
235.00
300.00
943.00
1,054.00
1,395.00
1,121
Total Investments and Advances
199.00
199.00
199.00
199.00
199.00
699
Other Assets
32.00
108.00
7.00
-
-
-
Total Assets
105,886.00
127,204.00
214,917.00
151,710.00
149,040.00
122,944
ST Debt & Current Portion LT Debt
5,928.00
3,436.00
-
-
-
Accounts Payable
1,881.00
4,105.00
2,857.00
2,555.00
5,306.00
Other Current Liabilities
5,382.00
9,735.00
7,840.00
8,940.00
13,219.00
Total Current Liabilities
13,191.00
17,276.00
10,697.00
11,495.00
18,525.00
Long-Term Debt
4,560.00
1,124.00
-
-
-
Other Liabilities
327.00
238.00
165.00
162.00
105.00
Total Liabilities
18,078.00
18,638.00
10,862.00
11,657.00
18,630.00
Common Equity (Total)
87,808.00
108,566.00
204,055.00
140,053.00
130,410.00
Total Shareholders' Equity
87,808.00
108,566.00
204,055.00
140,053.00
130,410.00
Total Equity
87,808.00
108,566.00
204,055.00
140,053.00
130,410.00
Liabilities & Shareholders' Equity
105,886.00
127,204.00
214,917.00
151,710.00
149,040.00

About Tetraphase Pharmaceuticals

View Profile
Address
480 Arsenal Street
Watertown Massachusetts 02472
United States
Employees -
Website http://www.tphase.com
Updated 07/08/2019
Tetraphase Pharmaceuticals, Inc. engages in the development and production of novel antibiotics for serious and life-threatening bacterial infections. It is currently developing a product candidate, eravacycline, a fully synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Watertown, MA.